Search ARM

Novellus is an Engineered Cellular Medicine company located in Cambridge, MA. We use our patented, high efficiency mRNA-based Gene Editing and Cell Reprogramming platforms to develop medicines for patients with devastating diseases such as AAT deficiency, Parkinson’s, Crohn’s disease, Dystrophic Epidermolysis Bullosa, and for next generation CAR-T/NK, next generation MSCs, dermatologic, ophthalmic, neurologic, inflammatory, gastrointestinal, hematologic, rare diseases and wound healing. Our patents cover mRNA CRISPRs technology and our proprietary, high specificity gene editing protein: NoveSlice™. We engineer precision medicines tailored to patient segments, and select from our technology toolbox for in vivo and ex vivo delivery including allogeneic and autologous medicines. We have strong IP covering RNA gene editing and RNA cell reprogramming, including 30 granted patents. We are seeking strategic partners to co-develop and commercialize drug candidates.

Contact Novellus
info@novellus-inc.com
Visit Website